Nvidia Corp (NASDAQ:NVDA) announced that it will partner with Aidoc, a startup that offers healthcare organizations artificial intelligence (AI) tools to improve workflows, data accuracy, and overall patient care.
The companies will work on a new framework, “Blueprint for Resilient Integration and Deployment of Guided Excellence” (BRIDGE), a guideline that aims to accelerate AI adoption across the healthcare industry.
Also Read: Microsoft Unveils Health Care AI Tools To Help Analyze Biomedical Data.
The guideline, scheduled for release in early 2025, will introduce a comprehensive, evidence-based framework for more effectively integrating AI into clinical workflows.
It aims to enable healthcare organizations to accelerate AI innovation with increased confidence. The guideline will outline strategies for healthcare systems to fully leverage AI’s potential in enhancing patient outcomes.
Although more than 900 FDA-cleared AI tools for medical imaging have been approved, healthcare systems still face fragmentation, operational inefficiencies, and scalability challenges.
The BRIDGE guideline will offer a vendor-neutral, all-encompassing roadmap to tackle these issues, empowering providers to realize AI’s benefits fully.
“AI holds the potential to revolutionize patient care, but its progress has been stalled by fragmented systems and the inability to scale effectively,” said Demetri Giannikopoulos, Chief Transformation Officer, Aidoc. “The BRIDGE guideline will focus on breaking down these barriers, offering a powerful, evidence-based framework that health systems can rely on not just adopt AI but to help scale it across their operations. This will drive both operational efficiency and significantly better outcomes for patients and clinicians alike.”
The BRIDGE guideline aims to establish a foundation aligned with industry frameworks like MONAI, which will serve as the blueprint for the medical AI enterprise platform.
MONAI, co-founded in 2019 by academia and industry leaders, including NVIDIA, offers essential tools for developing, validating, and deploying medical AI.
With over three million downloads and active use in FDA-approved software-as-medical-device applications, MONAI’s emphasis on standardization, interoperability, and scalability is crucial to driving transformative healthcare solutions.
Price Action: NVDA stock is up 0.32% at $138.32 at last check Monday.
Read Next:
Photo by PopTika on Shutterstock
